Related Experiment Video

Updated: Jun 23, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

[Effect of phenylhexyl isothiocyanate on adriamycin resistance of K562/A02 cell line]

Peng Yuang1, Bao-An Chen, Jian Cheng

  • 1Department of Hematology, Zhongda Hospital, College of Clinical Medicine, Southeast University, Nanjing 210009, Jiangsu Province, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|April 22, 2009
PubMed

Insights

Phenylhexyl isothiocyanate (PHI) enhances adriamycin (ADM) sensitivity in K562/A02 cells by increasing apoptosis and ADM uptake. This combination therapy may reduce ADM dosage and side effects.

Area of Science:

  • Pharmacology
  • Cancer Biology
  • Drug Resistance

Context:

  • Multidrug resistance (MDR) is a major challenge in cancer chemotherapy.
  • The K562/A02 cell line exhibits resistance to adriamycin (ADM).
  • Phenylhexyl isothiocyanate (PHI) is investigated as a potential chemosensitizer.

Purpose:

  • To investigate the effect of PHI on ADM sensitivity and resistance in K562/A02 cells.
  • To elucidate the underlying mechanisms of PHI's action.
  • To assess the potential of PHI-ADM combination therapy.

Summary:

  • PHI treatment decreased K562/A02 cell survival and increased apoptosis when combined with ADM.
  • PHI significantly altered drug resistance multiple and intracellular ADM concentrations at concentrations above 20 micromol/L.
  • PHI's cytotoxicity was not linked to intracellular glutathione (GSH) depletion; however, combined treatment reduced GSH levels.
  • MRP1 mRNA and protein expression remained unchanged, suggesting PHI's mechanism is independent of MRP1 modulation.

Impact:

  • PHI enhances ADM sensitivity and partially reverses ADM resistance in K562/A02 cells.
  • Combination therapy with PHI and ADM may allow for reduced ADM dosage and diminished side effects.
  • This study provides a basis for developing novel therapeutic strategies against MDR cancers.

More Related Videos

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi07:56

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Published on: August 18, 2010

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...